Medicine

  • FTC Brushes Off Bristol's Attempt to Scrub Generic Competition
    M. June Casalmir and Bernard Rhee of Bryan Cave LLP

    On March 7, the FTC announced its settlement of claims against Bristol Myers Squibb ("Bristol") for employing patent listings in the FDA's "Orange Book" to delay the entry of generic competitors for three of Bristol's brand name pharmaceutical products. The settlement is the latest in a series of initiatives by the agency aimed at preventing misuse of Hatch-Waxman Act proceedings to forestall competition in the pharmaceutical markets—and yet another sign that protecting generic entry and expansion is serious business to the FTC.

  • The Right Prescription
    Mitratech

    Pfizer's Global Security department, one of 11 different practice groups within the pharmaceutical company's worldwide Legal Division, had a problem. Charged with protecting the company's products from fraudulent imitations, thefts and other threats, Global Security needed an efficient system for tracking suspected counterfeit and stolen drugs, while expediting lab testing, ensuring accurate chain-of-custody documentation and automating appropriate - and secure - information sharing.

FindLaw Career Center